{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '6.2.', 'Preparation/Handling/Storage/Accountability', '31', '6.3.', 'Randomization and Blinding', '31', '6.3.1.', 'Randomization', '31', '6.3.2.', 'Assignment of Investigational Product Bottle Numbers', '31', '6.3.3.', 'Unblinding of an Individual Subject', '31', '6.4.', 'Investigational Product Compliance', '32', '6.5.', 'Concomitant Therapy', '33', '6.5.1.', 'Prohibited and Restricted Medications Prior to the Screening Visit and', 'Throughout the Study', '33', '6.6.', 'Dose Modification', '33', '6.7.', 'Intervention After the End of the Study', '33', '7.', 'DISCONTINUATION OF INVESTIGATIONAL PRODUCT AND', 'SUBJECT DISCONTINUATION/WITHDRAW', '33', '7.1.', 'Discontinuation of Investigational Product', '33', '7.1.1.', 'Pregnancy', '34', '7.1.2.', 'Liver Safety', '34', '7.2.', 'Subject Withdrawal from the Study', '34', '7.3.', 'Lost to Follow-up', '35', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', '35', '8.1.', 'Efficacy Assessments', '37', '8.1.1.', 'SNOT-22', '37', '8.1.2.', 'Computer Tomography (CT)', '38', '8.1.3.', 'Bilateral Endoscopic Nasal Polyp Score', '38', '8.1.4.', 'Disease-specific, Daily Symptom Assessments', '39', '8.1.5.', 'Smell Test: University of Pennsylvania Smell Identification Test (UPSIT)', '39', '8.1.6.', 'CRS Exacerbation', '40', '8.1.7.', 'Visual Analog Scale (VAS)', '40', '8.1.8.', 'Nitric Oxide Measurement', '40', '8.1.9.', 'Other Assessments', '40', '8.2.', 'Safety Assessments', '41', '8.2.1.', 'Physical Examinations', '41', '8.2.2.', 'Vital Signs', '41', '7', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '8.2.3.', 'Electrocardiograms', '41', '8.2.4.', 'Clinical Safety Laboratory Assessments', '41', '8.3.', 'Adverse Events, Serious Adverse Events, and Adverse Events of Interest', '42', '8.3.1.', 'Time Period and Frequency for Collecting AE and SAE Information', '42', '8.3.2.', 'Method of Detecting AEs and SAEs', '42', '8.3.3.', 'Follow-up of AEs and SAEs', '43', '8.3.4.', 'Regulatory Reporting Requirements for SAEs', '43', '8.3.5.', 'Pregnancy', '43', '8.3.6.', 'Death Events', '43', '8.3.7.', 'Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as', 'AEs or SAEs', '43', '8.4.', 'Treatment of Overdose', '44', '8.5.', 'Pharmacokinetics', '44', '8.6.', 'Pharmacodynamics and Biomarkers', '45', '8.6.1.', 'Nasal Biomarker Sample', '45', '8.6.2.', 'Blood Biomarker Analyses', '45', '8.6.3.', 'RNA Transcriptome Research', '45', '8.7.', 'Pharmacogenetics', '46', '9.', 'STATISTICAL CONSIDERATIONS', '46', '9.1.', 'Statistical Hypotheses', '46', '9.2.', 'Sample Size Determination', '46', '9.3.', 'Populations for Analyses', '46', '9.4.', 'Statistical Analyses', '47', '9.4.1.', 'Efficacy Analyses', '47', '9.4.1.1.', 'Primary Efficacy Analysis', '47', '9.4.1.2.', 'Secondary Efficacy Analysis', '47', '9.4.2.', 'Safety Analyses', '48', '9.5.', 'Interim Analyses', '48', '10.', 'APPENDICES', '49', '10.1.', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations (site', 'responsibilities)', '49', '8', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}